Accelerating Antibody Discovery With Advanced Label-Free Technology
The development of antibodies for diagnostics or therapeutics requires comprehensive characterization of affinity, specificity and mechanism of action. In particular, antibody-drug conjugates (ADCs) are an exciting and emerging class of biopharmaceuticals with applications in cancer.
Biolayer Interferometry (BLI) is a label free technique that is widely used for the quantitation of antibodies, which is fundamental to biological research and production processes. The technology is also extensively used for kinetics measurements of antibodies and small molecules to assess the strength and speed of binding of an antibody to a target.
This eBook explores advances in biosensor technology and instrumentation that can significantly accelerate antibody discovery through efficient quantitation, kinetics and epitope binning.
Download this eBook to learn more about :
- How to overcome ADC manufacturing challenges
- Multi-specific Ab analytical strategies
- Advances in BLI biosensors for robust antibody quantitation